Open AccessPembrolizumab Maintains Survival Benefit in Advanced Hepatocellular Carcinoma
Author(s) -
Mark L. Fuerst
Publication year - 2021
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000735076.22440.04
Subject(s) - sorafenib , pembrolizumab , medicine , hepatocellular carcinoma , placebo , adverse effect , interim analysis , carcinoma , oncology , clinical trial , gastroenterology , surgery , cancer , immunotherapy , pathology , alternative medicine